Cordis corporate warning letter resolved
This article was originally published in The Gray Sheet
Executive Summary
Johnson & Johnson's stent subsidiary finally resolves a 2004 corporate warning letter with FDA June 14. Agency inspectors had cited Cordis for quality systems noncompliance, particularly issues relating to handling of safety complaints with the Cypher drug-eluting stent at five different facilities (1"The Gray Sheet" April 12, 2004, p. 3). The company does not expect any new FDA approvals soon as a direct result of the warning letter resolution; Cordis' Precise carotid stent had been held up by the warning letter, but that product was approved last October...